The power of knowing in just 20min with no needles, no radiation and no surgery
Salt Lake City, UT, June 5, 2023 – IONIQ Sciences envisions a world where your annual check-up includes a Multi-Cancer Screen. In just 20 minutes, you could know – with no needles, no radiation and no surgery.
“If there was a test that could reassure people that a lesion was malignant or benign, that would be spectacular. It would cut costs, it would cut the risk to patients, and it would change the risk/benefit ratio for the early detection of lung cancer.” Dr. John Ruckesdeschel.
Our breast cancer test is currently moving through clinical trials. Preliminary clinical trial results were recently published in IEEE journal.
About IONIQ Sciences, Inc.
IONIQ Sciences, Inc. is developing an advanced multi-cancer screening technology for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. IONIQ Sciences operates at the confluence of its Electrical Impedance Analytics (EIA) or bioimpedance technology and Artificial Intelligence (AI). IONIQ Science’s first product utilizing its proprietary analytic platform, the IONIQ ProLung Test™ for lung cancer, has been designated a Breakthrough Device by the U.S. FDA.
IONIQ Sciences is proud to be a key supporter and member of the newly formed BioHive, a collective representing the life science and healthcare innovation ecosystem. By embracing diversity and collaboration, BioHive has become the fastest-growing life science community in America and their innovations are improving the lives of millions of patients. To learn more, please visit: www.biohive.com.
For further information about IONIQ Sciences, Inc., please contact:
Andy Robertson | 1-801-736-0729 | acr@IONIQsciences.com
IONIQ Sciences, Vice President of Business Development
IONIQ Sciences, Inc.
350 W. 800 N., Suite 214
Salt Lake City, Utah 84103